Literature DB >> 33519825

Myeloid-Derived Suppressor Cell Differentiation in Cancer: Transcriptional Regulators and Enhanceosome-Mediated Mechanisms.

Norman Fultang1, Xinyuan Li1, Ting Li1, Youhai H Chen1.   

Abstract

Myeloid-derived Suppressor Cells (MDSCs) are a sub-population of leukocytes that are important for carcinogenesis and cancer immunotherapy. During carcinogenesis or severe infections, inflammatory mediators induce MDSCs via aberrant differentiation of myeloid precursors. Although several transcription factors, including C/EBPβ, STAT3, c-Rel, STAT5, and IRF8, have been reported to regulate MDSC differentiation, none of them are specifically expressed in MDSCs. How these lineage-non-specific transcription factors specify MDSC differentiation in a lineage-specific manner is unclear. The recent discovery of the c-Rel-C/EBPβ enhanceosome in MDSCs may help explain these context-dependent roles. In this review, we examine several transcriptional regulators of MDSC differentiation, and discuss the concept of non-modular regulation of MDSC signature gene expression by transcription factors such as c-Rel and C/EBPß.
Copyright © 2021 Fultang, Li, Li and Chen.

Entities:  

Keywords:  aberrant myelopoiesis; enhanceosome; immunosuppression; myeloid-derived suppressor cell; tumor immunobiology

Year:  2021        PMID: 33519825      PMCID: PMC7840597          DOI: 10.3389/fimmu.2020.619253

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  101 in total

1.  The growing diversity and spectrum of action of myeloid-derived suppressor cells.

Authors:  Alberto Mantovani
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

Review 2.  Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Authors:  Hua Yu; Marcin Kortylewski; Drew Pardoll
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

3.  Lnc-C/EBPβ Negatively Regulates the Suppressive Function of Myeloid-Derived Suppressor Cells.

Authors:  Yunhuan Gao; Wei Sun; Wencong Shang; Yuanyuan Li; Dan Zhang; Tianze Wang; Xipeng Zhang; Shiwu Zhang; Yuan Zhang; Rongcun Yang
Journal:  Cancer Immunol Res       Date:  2018-08-31       Impact factor: 11.151

4.  Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.

Authors:  Yulia Nefedova; Mei Huang; Sergei Kusmartsev; Raka Bhattacharya; Pingyan Cheng; Raoul Salup; Richard Jove; Dmitry Gabrilovich
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

5.  Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.

Authors:  Cesar A Corzo; Matthew J Cotter; Pingyan Cheng; Fendong Cheng; Sergei Kusmartsev; Eduardo Sotomayor; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

6.  Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs.

Authors:  Chiara Porta; Francesca Maria Consonni; Sara Morlacchi; Sabina Sangaletti; Augusto Bleve; Maria Grazia Totaro; Paola Larghi; Monica Rimoldi; Claudio Tripodo; Laura Strauss; Stefania Banfi; Mariangela Storto; Tiziana Pressiani; Lorenza Rimassa; Silvia Tartari; Alessandro Ippolito; Andrea Doni; Giulia Soldà; Stefano Duga; Viviana Piccolo; Renato Ostuni; Gioacchino Natoli; Vincenzo Bronte; Fiorella Balzac; Emilia Turco; Emilio Hirsch; Mario P Colombo; Antonio Sica
Journal:  Cancer Res       Date:  2020-04-07       Impact factor: 12.701

7.  A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells.

Authors:  L M Scott; C I Civin; P Rorth; A D Friedman
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

8.  An array of coactivators is required for optimal recruitment of TATA binding protein and RNA polymerase II by promoter-bound Gcn4p.

Authors:  Hongfang Qiu; Cuihua Hu; Sungpil Yoon; Krishnamurthy Natarajan; Mark J Swanson; Alan G Hinnebusch
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

9.  The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow.

Authors:  Malene Digmann Bjerregaard; Jesper Jurlander; Pia Klausen; Niels Borregaard; Jack Bernard Cowland
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

10.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors:  David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

View more
  4 in total

1.  The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.

Authors:  Defne Bayik; Juyeun Lee; Justin D Lathia
Journal:  Exp Suppl       Date:  2022

2.  c-Rel-dependent monocytes are potent immune suppressor cells in cancer.

Authors:  Ting Li; Mayassa J Bou-Dargham; Norman Fultang; Xinyuan Li; Warren S Pear; Honghong Sun; Youhai H Chen
Journal:  J Leukoc Biol       Date:  2022-06-13       Impact factor: 6.011

3.  The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy.

Authors:  Claudia Urueña; Paola Lasso; David Bernal-Estevez; Diego Rubio; Ana Janeth Salazar; Mercedes Olaya; Alfonso Barreto; Mauricio Tawil; Lilian Torregrosa; Susana Fiorentino
Journal:  Sci Rep       Date:  2022-05-13       Impact factor: 4.996

Review 4.  Myeloid-derived suppressor cells and vaccination against pathogens.

Authors:  Estefanía Prochetto; Eliana Borgna; Carlos Jiménez-Cortegana; Víctor Sánchez-Margalet; Gabriel Cabrera
Journal:  Front Cell Infect Microbiol       Date:  2022-09-29       Impact factor: 6.073

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.